<unk>  is indicated in the management of congestive heart failure (CHF), commonly as an adjunct to angiotensin-converting-enzyme inhibitor (ACE inhibitors) and diuretics. It has been clinically shown to reduce mortality and hospitalizations in people with CHF. The mechanism behind its positive effect when used long-term in clinically stable CHF patients is not fully understood, but is thought to contribute to remodeling of the heart, improving upon its structure and function. The use of<unk>  has demonstrated a statistically significant reduction in death following a heart attack in patients with heart failure.<unk>  has also been proven to reduce death and hospitalizations in patients with severe heart failure. This includes hospitalization for any reason or for a<unk> diovascular reason including worsening heart failure, a heart attack, or an increased or irregular heartbeat. In practice,<unk>  has been used in the treatment of uncomplicated hypertension, yet studies suggest it has relatively ineffective blood pressure-lowering effects when compared with other blood pressure-lowering therapies or other beta blockers. Available forms<unk>  is available in the following forms: * Oral tablet * Extended-release (24-hour) oral capsule (approved by the FDA in 2006)
Carvedilol
Metoprolol
Digoxin
Digitoxin
Bisoprolol
Sotalol
Diltiazem
Captopril